| Name | Title | Contact Details |
|---|
NeuroLogica Corporation is a Danvers, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Sirius Medicine is a Loveland, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Rich history mixed with innovative technology is an integral part of Flagler Hospital in historic St. Augustine, Florida. Since its founding in 1889, our private, not-for-profit facility has grown into a 335 bed, acute care center that is consistently recognized nationally for overall clinical excellence. The hospital has consistently ranked among the top 5% in the nation for clinical excellence and patient safety for nearly a decade and was Northeast Florida`s first hospital to receive the ANCC Magnet hospital award. Most recently, the hospital earned five stars for heart attack treatment, the Gold Seal of Approval™ from The Joint Commission for Primary Stroke Care Centers, Center of Excellence Designation for its Bariatric Surgery Center, and national accreditation for total knee and total hip replacement surgery.
PROTAC, LLC, Is a 100% veteran-owned small business that offers a variety of training and health programs for service members and athletes.
Relmada Therapeutics (OTCQB: RLMD) is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of chronic pain. Relmada has a diversified portfolio of four lead products at various stages of development including d-Methadone (REL-1017) its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; topical mepivacaine (REL-1021), its orphan drug designated topical formulation of the local anesthetic mepivacaine; oral buprenorphine (REL-1028) its oral dosage form of the opioid analgesic buprenorphine; and LevoCap ER (REL-1015), its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol. Relmada`s product development efforts are guided by the internationally recognized scientific expertise of our research team. Relmada`s approach is expected to reduce clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs.